What's New: July 2026 Update TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program NDA timeline on track: industry estimates continue to expect Q4 2026 filing, following TRIUMPH-1's positive readout Introduction The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches
AI has compressed the path from target discovery to clinical candidates by screening billions of molecules in silico, estimating binding, safety risks, and pharmacokinetics before anything reaches the lab
Yesby improving metabolism and supporting fat processing, Skinny Shots can enhance weight loss efforts when combined with a balanced diet and exercise routine
Ben Blanc 00:45 You know, you really cant escape it here
Meanwhile, emerging economies such as Brazil, Chile, and Greece are seeing steady increases in obesity rates while maintaining limited healthcare budgets, creating opportunities for scalable and cost-effective treatment approaches
Any product sold online or by a compounding pharmacy as "retatrutide" is, at best, a research chemical of uncertain identity and purity, and at worst what the FDA called out in its May 2026 warning letter unapproved drug products misbranded for human use
